A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
Phase 1
29
about 5.4 years
≤25
1 site in TN
About this study
This trial is testing dalbavancin, a medication, as a preventative measure against bacterial infections in children and adolescents with leukemia who are receiving chemotherapy. The goal is to see how effective this treatment is at preventing bloodstream infections and other complications.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Dalbavancin
- 2.Take Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician)
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
dalbavancin, antibiotic (Fluoroquinolone antibiotic; inhibits bacterial DNA gyrase)
injection, intravenous, oral (Oral Tablet)
Secondary: Dalbavancin peak plasma concentration (Cmax) - Median and range, Tolerability of dalbavancin
Oncology